Be Tobacco Free is a resource about tobacco products, laws, health risks, and how to prevent and stop using tobacco
[1] Serious risks include nicotine poisoning and continued addiction
By: Sanjeet Bagcchi Send to a friend The details you provide on this page will not be used to send unsolicited email, and will not be sold to a 3rd party
As a result, more people are dying from cigarettes or developing lung cancer, compared to the 1950s or 60s
CHANTIX has also been studied in postmarketing trials including (1) a trial conducted in patients with chronic obstructive pulmonary disease (COPD), (2) a trial conducted in generally healthy patients (similar to those in the premarketing studies) in which they were allowed to select a quit date between days 8 and 35 of treatment (alternative quit date instruction trial), (3) a trial conducted in patients who did not succeed in stopping smoking during prior CHANTIX therapy, or who relapsed after treatment (re-treatment trial), (4) a trial conducted in patients with stable cardiovascular disease, (5) a trial conducted in patients with stable schizophrenia or schizoaffective disorder, (6) a trial conducted in patients with major depressive disorder, (7) a postmarketing neuropsychiatric safety outcome trial in patients without or with a history of psychiatric disorder, and (8) a trial in patients who were not able or willing to quit abruptly and who were instructed to quit gradually (gradual approach to quitting smoking trial)
